Table 3.
Effect-dosage relationship of the inhibition of the expression of EGFP under the control of the Cp and Xp promoters by β-LPA
| Dosage (μmol/L) | n |
EGFP-positive cells (%) (mean ± SD) |
Inhibition rate (%) |
||
| Cp | Xp | Cp | Xp | ||
| Control | 3 | 13.99 ± 0.29 | 18.58 ± 0.39 | 0.0 | 0.0 |
| (Lamivudine) | 4 | 13.80 ± 0.63 | 18.46 ± 0.49 | 1.3 | 0.6 |
| 0.002 | 4 | 12.98 ± 0.16b | 17.54 ± 0.31b | 7.2 | 5.6 |
| 0.01 | 4 | 11.96 ± 0.75b | 16.18 ± 0.21b | 14.5 | 12.9 |
| 0.05 | 4 | 10.88 ± 0.43b | 14.63 ± 0.37b | 22.2 | 21.3 |
| 1 | 4 | 8.79 ± 0.56b | 11.94 ± 1.37b | 37.7 | 35.7 |
b
P < 0.01 vs Blank control. EGFP: Enhanced green fluorescent protein.